Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

David Spigel, MD, on the use of genomic markers like TMB to guide 1st NSCLC treatment

Dr. Spigel, Chief Scientific Officer, Director, Lung Cancer Research Program, Sarah Cannon, on the use of genomic markers like tumor mutational burden (TMB) to guide first line treatment in patients with PD-L1 positive non-small cell lung cancer (NSCLC)

Tags: ESMO 2019Lung (includes NSCLC, SCLC, Mesothelioma)Personalized Oncology (includes Cancer Genetics)

Published: 29 September 2019

Recent Videos: Personalized Oncology (includes Cancer Genetics)

video

David Spigel, MD, on the use of genomic markers like TMB to guide 1st NSCLC treatment

Dr. Spigel, Chief Scientific Officer, Director, Lung Cancer Research Program, Sarah Cannon, on the use of genomic markers like tumor ...

video

Suresh Ramalingam, MD, discusses the results of CheckMate 227 in advanced NSCLC patients

Dr. Ramalingam, Professor of Hematology & Medical Oncology, Director, Lung Cancer Program, Winship Cancer Institute of Emory University, discusses if ...

Related Videos

video-image

Suresh Ramalingam, MD, discusses the results of CheckMate 227 in advanced NSCLC patients

video-image

NGS and Cancer: Combatting the Hazards of Misinformation

video-image

Will NGS-Based Cancer Tests Become Routine?

video-image

Next-Gen Sequencing is Transforming Oncology Practices

video-image

Randall A. Oyer, MD, explains how ACCC is interpreting the data on genetics presented at ASCO 2018

video-image

Melissa Johnson, MD, on lung cancer patients that have a PD-L1 expression that is less than 1%

video-image

Melissa Johnson, MD, on stratifying newly diagnosed lung cancer patients with the PD-L1 biomarker

video-image

Melissa Johnson, MD, clarifies how physicians should use the PD-L1 biomarker

video-image

Noa Biran, MD, offers opinion on how personalized medicine will impact treatment of multiple myeloma

video-image

Sundar Jagannath, MD, on the impact of personalized medicine in treatment of multiple myeloma

video-image

Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes

video-image

Jonathan Hirsch, discusses how precision medicine is being used to help improve cancer treatment

video-image

Bobby Green, MD, on using genomic data to prescreen eligibility for clinical trials

video-image

Bobby Green, MD, discusses collaboration efforts between Flatiron and Foundation Medicine

video-image

Bobby Green, MD, on leveraging genomic testing into actionable data

video-image

Shirish M. Gadgeel MBBS, comments on significant studies in ALK+ NSCLC from ESMO 2019

video-image

Véronique Diéras, MD, on the optimal setting in which to receive a PARP inhibitor

video-image

Robert L. Coleman, MD, FACOG, FACS, on takeaways from the ovarian plenary session at ESMO '19

video-image

Amer Zeidan, MBBS, comments on the influx of investigational oral agents in myeloid malignancies

video-image

Arndt Vogel, MD, elaborates on some of the key takeaways from the GO30140 trial

video-image

George Sledge, MD, explains how MONARCH-2 may impact the current standard of care

video-image

Dennis J. Slamon, MD, PhD, discusses implications from the MONALEESA-3 trial

video-image

Nader Sanai, MD, offers perspective on the challenges in treating glioblastoma

video-image

Christian Rolfo, MD, PhD, MBA, on the role of liquid biopsy in the treatment of lung cancer

video-image

Ulrik Lassen, MD, PhD, on whether testing for TRK fusion is easy and reliable

video-image

Scott Kopetz, MD, explains how BRAF mutations figure into treatment algorithms for CRC

video-image

Stefan Kasper, MD, provides updates on the BEACON trial in BRAF-mutant CRC

video-image

Shirish M. Gadgeel MBBS, speculates on the future of RET-altered NSCLC

video-image

Véronique Diéras, MD, on BRCA-positive metastatic breast cancer & PARP inhibitors

video-image

Robert L. Coleman, MD, FACOG, FACS, on the VELIA, PAOLA-1 and PRIMA studies

video-image

Amer Zeidan, MBBS, on his study investigating onvansertib + cytarabine or decitabine in AML

video-image

Arndt Vogel, MD, elaborates on the results of the CheckMate-459 study in HCC

video-image

Brian Van Tine, MD, shares some of the top studies in sarcoma presented at ESMO 2019

video-image

George Sledge, MD, shares the most relevant findings from the MONARCH-2 trial

video-image

Dennis J. Slamon, MD, PhD, on the significance of the phase III MONALEESA-3 trial

video-image

Deborah Shrag, MD, MPH, on which biomarkers are important in the diagnosis & management of CRC

video-image

Nader Sanai, MD, shares details from the most promising studies in glioma presented at ESMO 2019

video-image

Christian Rolfo, MD, PhD, MBA, on the development of RET-Fusion in NSCLC

video-image

Ulrik Lassen, MD, PhD, discusses the incidence of TRK fusion in various tumor types

video-image

Scott Kopetz, MD, shares updates from the BEACON trial in BRAF-mutant colorectal cancer

video-image

Stefan Kasper, MD, explains the dosing and administration schedule of cetuximab

video-image

Shirish M. Gadgeel MBBS, regarding the most exciting data in lung cancer from ESMO 2019

video-image

Véronique Diéras, MD, elaborates on the BROCADE 3 study presented at ESMO 2019

video-image

Robert L. Coleman, MD, FACOG, FACS, on how veliparib factors into ovarian cancer treatment

video-image

Brian Van Tine, MD, considers the role of real-world outcomes in the treatment of sarcoma

video-image

Arndt Vogel, MD, offers his opinion on pemigatinib in the management of cholangiocarcinoma

video-image

Jason J. Luke, MD, FACP, on the role of CAR-Ts in the treatment of solid tumors

video-image

Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

video-image

David Gershenson, MD, on considerations for maintenance therapy in ovarian cancer

video-image

Banu Arun, MD, on PARP inhibitors in BRCA positive metastatic breast cancer

video-image

David Gershenson, MD, tells us what's new in the treatment of rare epithelial cancers

video-image

Banu Arun, MD, regarding veliparib in breast cancer patients with BRCA mutations

video-image

David Gershenson, MD, elaborates on the role of MEK inhibitor trametinib in LGSC

video-image

Arndt Vogel, MD, shares his impression of the FIGHT-202 trial in cholangiocarcinoma

video-image

Ahmed Kaseb, MD, considers the effectiveness of bevacizumab + atezolizumab in HCC

video-image

Brian Van Tine, MD, discusses the design of the SPEARHEAD-1 trial

video-image

Jason J. Luke, MD, FACP, on the most compelling data in metastatic melanoma from ESMO 2019

video-image

Ahmed Kaseb, MD, elaborates on the phase 1b study investigating atezolizumab + bevacizumab in HCC

video-image

Christopher J. Hoimes, MD, considers the role of I-O in perioperative muscle-invasive bladder cancer

video-image

Brian Van Tine, MD, on the most promising investigational agents in advanced sarcoma

video-image

Jason J. Luke, MD, FACP, on how data from ESMO 2019 may impact the treatment of melanoma

video-image

Ahmed Kaseb, MD, offers opinion on nivolumab + ipilimumab in resectable HCC

video-image

Christopher J. Hoimes, MD, comments on the design and outcomes of KEYNOTE-866

video-image

Joyce O’Shaughnessy, MD, elaborates on the MONALEESA-3 trial presented at ESMO 2019

video-image

Christopher J. Hoimes, MD, regarding the EV-103 study presented at ESMO 2019

video-image

Joyce O’Shaughnessy, MD, shares relevant findings from the MONARCH-2 trial

video-image

Geoffrey Oxnard, MD, on the effectiveness of lorlatinib as a frontline agent in ALK+ NSCLC

video-image

Joyce O’Shaughnessy, MD, on the role of CDK4/6 inhibitors in the management of TNBC

video-image

Geoffrey Oxnard, MD, explains how genomic markers can guide treatment in PD-L1 positive NSCLC

video-image

Joyce O’Shaughnessy, MD, shares results of the Impassion130 trial presented at ESMO 2019

video-image

Suresh Ramalingam, MD, provides perspective on the PD-L1 and TMB biomarkers in lung cancer

video-image

David Spigel, MD, on how results from the FLAURA study impact treatment selection in lung cancer

video-image

Suresh Ramalingam, MD, offers opinion on optimal sequencing of immunotherapy in NSCLC

video-image

Michael J. Birrer, MD, PhD, considers the benefits of various PARP inhibitors in ovarian cancer

video-image

David Spigel, MD, tells us about the results of CheckMate-227 presented at ESMO 2019

video-image

Suresh Ramalingam, MD, on how the FLAURA trial may impact care for EGFR-mutated NSCLC

video-image

Marwan Fakih, MD, considers implications from the AMG 510 trial

video-image

Michael J. Birrer, MD, PhD, regarding BRCA status in newly diagnosed ovarian cancer

video-image

Michael J. Birrer, MD, PhD, on the role of maintenance therapy in newly diagnosed ovarian cancer

video-image

Michael J. Birrer, MD, PhD, elaborates on the outcomes from the FORWARD I study

video-image

Michael Birrer, MD, on the key takeaways from the ovarian plenary session in ovarian cancer at ESMO 2019

video-image

Joyce O’Shaughnessy, MD, on differentiating CDK4/6 inhibitors

video-image

Geoffrey Oxnard, MD, on the FLAURA study impacting treatment selection in EGFR mutant lung cancer

video-image

Marwan Fakih, MD, on whether MSI-high is a “must-have” biomarker for CRC patients

video-image

Nader Sanai, MD, on the role of ribociclib in the management of gliomas

video-image

Suresh Ramalingam, MD, FASCO, shares results from the FLAURA trial presented at ESMO 2019

video-image

Marwan Fakih, MD, discusses the Phase 1 trial evaluating AMG 510 in CRC and NSCLC

video-image

Sandip Patel, MD, on treatment in the 2nd line setting following PD-L1 targeting agents

video-image

Sandip Patel, MD, speculates on the impact of the RELAY trial presented at ASCO 2019

video-image

Shirish Madhav Gadgeel, MBBS, on treating patients who have already received PD-L1 targeting agents

video-image

Shirish Madhav Gadgeel, MBBS, offers opinion on the results of the RELAY trial from ASCO 2019

video-image

Lowell L. Hart, MD, FACP, regarding recent data investigating trilaciclib in SCLC

video-image

Sandip Patel, MD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Kristin Higgins, MD, offers opinion on the PACIFIC study in non-small cell lung cancer

video-image

Shirish Madhav Gadgeel, MBBS, on treating non-squamous NSCLC patients expressing high PD-L1

video-image

Marwan G. Fakih, MD, on why AMG 510 seems promising in colorectal and lung cancers

video-image

Sandip Patel, MD, comments on the top stories in lung cancer from ASCO 2019

video-image

Kristin Higgins, MD, shares her interpretation of the PACIFIC study in unresectable NSCLC

video-image

Shirish Madhav Gadgeel, MBBS, regarding the top stories in lung cancer from ASCO 2019

video-image

Naiyer Rizvi, MD, speculates on the future of drug development in NSCLC

video-image

Naiyer Rizvi, MD, offers thoughts on the role of blood TMB vs. tissue TMB

video-image

Naiyer Rizvi, MD, describes the role of PD-L1 & TMB biomarkers in the treatment of lung cancer

video-image

Naiyer Rizvi, MD, tells us about the results of Keynote-001 in NSCLC

video-image

Ravi Salgia, MD, PhD, considers the unmet medical needs in the treatment of NSCLC

video-image

Ravi Salgia, MD, PhD, on treatment in the 2nd line setting after 1st line PD-L1 targeting agents

video-image

Ravi Salgia, MD, PhD, on the ideal patient to receive Alimta plus Keytruda based on Keynote-189

video-image

Ravi Salgia, MD, PhD, on treating non-squamous, NSCLC patients with high levels of PD-L1

video-image

Ravi Salgia, MD, PhD, offers strategies for identifying PD-L1 status

video-image

Ravi Salgia, MD, PhD, outlines some of the molecular tests utilized prior to treating advanced NSCLC

video-image

Ravi Salgia, MD, PhD, comments on germline mutations & the impact on NSCLC patients

video-image

Edward B. Garon, MD, on the implications of Keynote-189

video-image

Edward B. Garon, MD, elaborates on the role of PD-L1 in the management of lung cancer

video-image

Edward B. Garon, MD, considers the implications of Keynote-001 in advanced NSCLC

video-image

Pasi A. Jänne, MD, PhD, regarding the unmet medical needs in the treatment of NSCLC

video-image

Pasi A. Jänne, MD, PhD, discusses some of the challenges in managing NSCLC

video-image

Martin E. Gutierrez, MD, discusses some of the top challenges in managing NSCLC

video-image

Pasi A. Jänne, MD, PhD, on treating patients in the 2nd line setting after 1st line Keytruda

video-image

Martin E. Gutierrez, MD, on 2nd line treatment options following 1st line PD-L1 targeting agents

video-image

Pasi A. Jänne, MD, PhD, elaborates on outcomes from the RELAY trial

video-image

Martin E. Gutierrez, MD, discusses the implications of the RELAY trial from ASCO 2019

video-image

Pasi A. Jänne, MD, PhD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Pasi A. Jänne, MD, PhD, on molecular testing prior to the treatment of advanced NSCLC

video-image

Martin E. Gutierrez, MD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Pasi A. Jänne, MD, PhD, on the study of U3-1402 in EGFR mutant NSCLC presented at ASCO 2019

video-image

Martin E. Gutierrez, MD, on the role of clinico-genomic data sharing in lung cancer treatment

video-image

Pasi A. Jänne, MD, PhD, on advances in the treatment of lung cancer being presented at ASCO 2019

video-image

Ravi Salgia, MD, PhD, offers opinion on the top challenges in managing NSCLC

video-image

Melissa Johnson, MD, shares her thoughts on biomarker development in NSCLC

video-image

Melissa Johnson, MD, speculates on exciting developments in the treatment of NSCLC

video-image

Melissa Johnson, MD, considers the recent data investigating atezolizumab in SCLC

video-image

Alexander Spira, MD, PhD, FACP, tells us the latest thinking regarding the PD-L1 biomarker

video-image

Alexander Spira, MD, PhD, FACP, on managing lung cancer patients in a community setting

video-image

Alexander Spira, MD, PhD, FACP, on the recent approval of atezolizumab in SCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

video-image

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC

video-image

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Benjamin Philip Levy, MD, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab

video-image

Benjamin Philip Levy, MD, comments on the IMpower150 clinical trial in NSCLC

video-image

Benjamin Philip Levy, MD, on options for NSCLC patients who progress on 1st line I-O & chemotherapy

video-image

Benjamin Philip Levy, MD, regarding combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Benjamin Philip Levy, MD, discusses the practice-changing outcomes from Keynote 189

video-image

Benjamin Philip Levy, MD, offers opinion on testing for PD-L1 expression in NSCLC

video-image

Howard (Jack) West, MD, regarding Tumor Mutation Burden (TMB) as a biomarker for NSCLC patients

video-image

Howard (Jack) West, MD, on maintenance therapy after carboplatin, pemetrexed & pembrolizimab

video-image

Howard (Jack) West, MD, discusses key takeaways from the IMpower150 study in NSCLC

video-image

Howard (Jack) West, MD, on treatment options for patients who progress on I-O & chemotherapy

video-image

Howard (Jack) West, MD, regarding the combination of immunotherapy & chemotherapy in NSCLC

video-image

Howard (Jack) West, MD, regarding PDL-1 expression and NSCLC

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, considers predictive biomarkers in NSCLC

video-image

Mohammad Jahanzeb, MD, FACP, discusses the significance of Keynote 42 from ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Mohammad Jahanzeb, MD, FACP, on the results of Keynote 189, PDL-1 expression and patient selection

video-image

Edgardo S. Santos, MD, FACP, on the benefits of combination docetaxel + ramucirumab

video-image

Edgardo S. Santos, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Edgardo S. Santos, MD, FACP, on the outcomes of Keynote 189 in metastatic NSCLC

video-image

Edgardo S. Santos, MD, FACP, discusses exciting developments out of ASCO 2018

video-image

Roy S. Herbst, MD, PhD, discusses the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

Roy S. Herbst, MD, PhD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

Roy S. Herbst, MD, PhD, on if patient selection will change as a result of Keynote 42

video-image

Roy S. Herbst, MD, PhD, on pemextrexed maintenance treatment

video-image

Roy S. Herbst, MD, PhD, shares what's exciting here at ASCO 2018

video-image

Roy S. Herbst, MD, PhD, on if Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

Joan Schiller, MD, regarding Keynote trials from ASCO 2018 & the influence on choice of therapy

video-image

Joan Schiller, MD, considers the validity of Tumor Mutation Burden (TMB) as a biomarker

video-image

Joan Schiller, MD, on the impact of Keynotes 189 & 42 on drug sequencing regimens

video-image

Joan Schiller, MD, regarding the results of Keynote 42 presented at the 2018 ASCO Annual Meeting

video-image

Joan Schiller, MD, considers the continuation of pemetrexed maintenance

video-image

Joan Schiller, MD, offers her opinion on Keynote 189 & PDL-1 expression and patient selection

video-image

David R. Gandara, MD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

David R. Gandara, MD, on what will change about patient selection as a result of Keynote 42

video-image

David R. Gandara, MD, on continuing pemextrexed maintenance

video-image

David R. Gandara, MD, on whether Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

David R. Gandara, MD, shares the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

David R. Gandara, MD, discusses exciting new developments in lung cancer here at ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, discusses the impact of Keynote 189 & 42 on drug sequencing regimens

video-image

Melissa Johnson, MD, on how Next Generation Sequencing is relevant to the treatment of NSCLC

video-image

Melissa Johnson, MD, discusses combinations and the treatment of lung cancer

video-image

Mary Jo Fidler, MD, FASCO, considers the biomarker challenges when treating SCLC

video-image

Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC

video-image

Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC

video-image

George Simon, MD, FACP, FCCP, regarding the most impactful clinical studies on lung cancer at ASCO

video-image

Edward Kim, MD, provides insight on how to use the PD-L1 biomarker to direct therapy

video-image

Edward Kim, MD, describes how immunotherapy combinations will be used in the near future

video-image

Edward Kim, MD, comments on gefitinib versus vinorelbine-cisplatin as adjuvant treatment in NSCLC

video-image

Edward Kim, MD, on anti-PD-L1/PD-1 combination therapies in treatment of lung cancer

video-image

Edward Kim, MD, offers his opinion on the biggest news in lung cancer before and during ASCO 2017

video-image

Phil Bonomi, MD, on immunotherapy for treatment of SCLC and mesothelioma

video-image

Phil Bonomi, MD, offers opinion on whether MET inhibitors are effective in metastatic NSCLC

video-image

Jack West, MD, shares his outlook on IDO inhibitors for treatment of lung cancer

video-image

Jack West, MD, on what we know about durvalumab in treatment of stage 3 NSCLC

video-image

Jack West, MD, on anti-PD-L1/PD-1 therapy in combination with chemotherapy & targeted therapies

video-image

Lyudmila Bazhenova, MD, on treating ALK+ lung cancer patients with ALK inhibitors

video-image

Jack West, MD, discusses PD-L1/PD-1 therapy in lung cancer treatment algorithms

video-image

Julie Brahmer, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

Julie Brahmer, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

video-image

David Ettinger, MD, talks about impact of immunotherapy in 1st line metastatic NSCLC patients

video-image

David Gandara, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

David Gandara, MD, discusses the positioning of Cyramza post platinum therapy in NSCLC patients

video-image

David Gandara, MD, discusses PD-L1 expression and selecting the appropriate agent in NSCLC patients

video-image

David Ettinger, MD, provides practical advice related to PD-L1 testing in metastatic NSCLC patients

video-image

Julie Brahmer, MD, provides practical advice related to PD-L1 testing in NSCLC patients

video-image

Julie Brahmer, MD, on the importance of overall cost of therapy

video-image

Julie Brahmer, MD, on the level of PD-L1 expression in selecting the appropriate agent in NSCLC

video-image

David Ettinger, MD, on cost of therapy when choosing agents for late stage lung cancer patients

video-image

David Ettinger, MD, on choosing between immunotherapy and chemotherapy in metastatic NSCLC patients

video-image

David Ettinger, MD, on the positioning of ramucirumab (Cyramza) for NSCLC

video-image

David Ettinger, MD, talks about levels of PD-L1 expression and agent selection

video-image

David Gandara, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

video-image

Julie Brahmer, MD, on positioning of ramucirumab (Cyramza) post-platinum therapy in NSCLC patients

video-image

David Gandara, MD, discusses pembrolizumab vs docetaxel for previously treated NSCLC patients

video-image

Phil Bonomi, MD, on importance of checkpoint inhibitors in first-line NSCLC setting

video-image

Phil Bonomi, MD, talks about the evolving role of targeted agents in 2nd line NSCLC and beyond

video-image

Phil Bonomi, MD, discusses costs of new lung cancer therapies relative to duration of therapy

video-image

Mohammad Jahanzeb, MD, FACP speaks about testing for PD-L1 in the first-line NSCLC setting